Toll-like receptors expression and interferon-γ production by NK cells in human sepsis

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Souza Fonseca Guimaraes, Fernando ^a   Parlato, Marianna ^a   Philippart, François ^b   Misset, Benoît ^b   Cavaillon, Jean Marc ^a   Adib Conquy, Minou ^a   Jacqmin, Sébastien ^c   Journois, Didier ^c   Lagrange, Alix ^c   de Villechenon, Gabrielle Pinot ^c   Aissaoui, Nadia ^c   Diehl, Jean Luc ^c   Guerot, Emmanuel ^c   Venot, Marion ^c   Hamzaoui, Olfa ^d   Prat, Dominique ^d   Sztrymf, Benjamin ^d   Maxime, Djillali Annane Virginie ^e   Polito, Andrea ^e   Bournaud, Elsa ^b   Bruel, Cédric ^b   Fournier, Julien ^b   Garrouste Orgeas, Maïté ^b   Gregoire, Charles ^b   Lau, Nicolas ^b   Max, Adeline ^b   Bouhemad, Belaïd ^b   Ethuin, Frédéric ^b   Bedos, Jean Pierre ^f   Crosnier, Pierrick ^f   Laurent, Virginie ^f   Merceron, Sybille ^f   Pachot, Alexandre ^g   Moucadel, Virginie ^g   more..

^a INSTITUT PASTEUR   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g BIOMÉRIEUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 18; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; BIOLOGICAL MARKER; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BACTERIUM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE STATUS; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; CASE CONTROL STUDY; CELL CULTURE; METABOLISM; MIDDLE AGED;

AGED; ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MALE; MIDDLE AGED; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTORS;

EID: 84867740346     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11838     Document Type: Article

References (65)

1. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. Scand J Infect Dis 2003, 35:535-544.
2. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009, 101:36-47.
3. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991, 88:1747-1754.
4. Marie C, Muret J, Fitting C, Losser MR, Payen D, Cavaillon JM. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998, 91:3439-3446.
5. Muret J, Marie C, Fitting C, Payen D, Cavaillon JM. Ex vivo T-lymphocyte derived cytokine production in SIRS patients is influenced by experimental procedures. Shock 2000, 13:169-174.
6. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183.
7. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006, 10:233.
8. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009, 30:475-487.
9. Draisma A, Pickkers P, Bouw M, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009, 37:1261-1267.
10. Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007, 7:703-714.
11. Weigent DA, Huff TL, Peterson JW, Stanton GJ, Baron S. Role of interferon in streptococcal infection in the mouse. Microb Pathog 1986, 1:399-407.
12. Nakano Y, Onozuka K, Terada Y, Shinomiya H, Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. J Immunol 1990, 144:1935-1941.
13. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 1992, 149:1666-1670.
14. Silva AT, Cohen J. Role of interferon-gamma in experimental Gram-negative sepsis. J Infect Dis 1992, 166:331-335.
15. Kohler J, Heumann D, Garotta G, Leroy D, Bailat S, Barras C, Baumgartner JD, Glauser MP. IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol 1993, 151:916-921.
16. Rayhane N, Fitting C, Cavaillon JM. Dissociation of IFN-gamma from IL-12 and IL-18 production during endotoxin tolerance. J Endoxtin Res 1999, 5:319-324.
17. Seki S, Osada S, Ono S, Aosasa S, Habu Y, Nishikage T, Mochizuki H, Hiraide H. Role of liver NK cells and peritoneal macrophages in gamma interferon and interleukin-10 production in experimental bacterial peritonitis in mice. Infect Immun 1998, 66:5286-5294.
18. Girardin E, Grau GE, Dayer JM, Rouxlombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of childrem with severe infectious purpura. N Engl J Med 1988, 319:397-400.
19. Adib-Conquy M, Cavaillon JM. Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J Biol Chem 2002, 277:27927-27934.
20. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, VolK HD, Kox W. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997, 3:678-681.
21. Souza-Fonseca-Guimaraes F, Adib-Conquy M, Cavaillon JM. Natural Killer (NK) Cells in Antibacterial Innate Immunity: Angels or Devils?. Mol Med 2012, 18:270-285.
22. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
23. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemont N, Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004, 104:1778-1783.
24. Lauzon NM, Mian F, MacKenzie R, Ashkar AA. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 2006, 241:102-112.
25. Varma TK, Lin CY, Toliver-Kinsky TE, Sherwood ER. Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Clin Diagn Lab Immunol 2002, 9:530-543.
26. Cowdery J, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996, 156:4570-4575.
27. Tsujimoto H, Uchida T, Efron PA, Scumia PO, Verma A, Matsumoto T, Tschoeke SK, Ungaro RF, Ono S, Seki S, Clare-Salzler MJ, Baker HV, Mochizuki H, Ramphal R, Moldawer LL. Flagellin enhances NK cell proliferation and, activation directly and through dendritic cell-NK cell interactions. J Leukoc Biol 2005, 78:888-897.
28. Athie-Morales V, O'Connor GM, Gardiner CM. Activation of human NK cells by the bacterial pathogen-associated molecular pattern muramyl dipeptide. J Immunol 2008, 180:4082-4089.
29. DeMarco RA, Fink MP, Lotze MT. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 2005, 42:433-444.
30. Holub M, Kluckova Z, Helcl M, Prihodov J, Rokyta R, Beran O. Lymphocyte subset numbers depend on the bacterial origin of sepsis. Clin Microbiol Infect 2003, 9:202-211.
31. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, Allombert C, Mougin B, Malcus C, Poitevin-Later F, Lepape A, Monneret G. Early assessment of leukocyte alteration at diagnosis of septic shock. Shock 2010, 34:358-363.
32. Maturana P, Puente J, Miranda D, Sepulveda C, Wolf ME, Mosnaim AD. Natural-killer-cell activity in patients with septic shock. J Crit Care 1991, 6:42-45.
33. Georgeson GD, Szony BJ, Streitman K, Kovacs A, Kovacs L, Laszlo A. Natural killer cell cytotoxicity is deficient in newborns with sepsis and recurrent infections. Eur J Pediatr 2001, 160:478-482.
34. Klimpel GR, Herndon DN, Fons M, Albrecht T, Asuncion MT, Chin R, Stein MD. Defective NK cell-activity following thermal-injury. Clin Exp Immunol 1986, 66:384-392.
35. Blazar BA, Rodrick ML, Omahony JB, Wood JJ, Bessey PQ, Wilmore DW, Mannick JA. Suppression of natural-killer-cell function in humans following thermal and traumatic injury. J Clin Immunol 1986, 6:26-36.
36. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005, 26:136-140.
37. Hiraki S, Ono S, Kinoshita M, Tsujimoto H, Seki S, Mochizuki H. Interleukin-18 restores immune suppression in patients with nonseptic surgery, but not with sepsis. Am J Surg 2007, 193:676-680.
38. Rangelfrausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural-history of the systemic inflammatory response syndrome (SIRS) - A prospective study. JAMA-J Am Med Assoc 1995, 273:117-123.
39. Flo TH, Halaas O, Torp S, Ryan L, Lien E, Dybdahl B, Sundan A, Espevik T. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 2001, 69:474-481.
40. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, Ruiz A, Cervantes R, Torres AP, Cabrera N, González A, Maldonado C, Isibasi A. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol 2003, 130:65-74.
41. Gerosa F, Tommasi M, Benati C, Gandini G, Libonati M, Tridente G, Carra G, Trinchieri G. Differential-effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity-induced by rIL-2, rIL-12 and rIFNalpha in human NK cells. Cell Immunol 1993, 150:382-390.
42. Schmidt KN, Leung B, Kwong M, Zarember KA, Satyal S, Navas TA, Wang F, Godowski PJ. APC-Independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA. J Immunol 2004, 172:138-143.
43. Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, Kondo T. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol 2008, 181:4208-4218.
44. Pachot A, Cazalis MA, Venet F, Turrel F, Faudot C, Voirin N, Diasparra J, Bourgoin N, Poitevin F, Mougin B, Lepape A, Monneret G. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol 2008, 180:6421-3429.
45. Zarife MAS, Reis EAG, Carmo TMA, Lopes GB, Brandio ECM, Silva HR, Santana N, Martins-Filho OA, Reis MG. Increased frequency of CD56(Bright) NK-cells, CD3(-)CD16(+)CD56(-) NK-cells and activated CD4(+)T-cells or B-cells in parallel with CD4(+)CDC25(high) T-cells control potentially viremia in blood donors with HCV. J Med Virol 2009, 81:49-59.
46. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol 2008, 180:6334-6345.
47. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
48. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H. Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care 2006, 10:R166.
49. Hodge G, Hodge S, Han P, Haslam R. Multiple leucocyte activation markers to detect neonatal infection. Clin Exp Immunol 2004, 135:125-129.
50. de Pablo R, Monserrat J, Reyes E, Diaz D, Rodriguez-Zapata M, de la Hera A, Prieto A, Alvarez-Mon M. Sepsis-induced acute respiratory distress syndrome with fatal outcome is associated to increased serum transforming growth factor beta-1 levels. Eur J Intern Med 2012, 23:358-362.
51. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002, 195:559-570.
52. Shuang C, Wong MH, Schulte DJ, Arditi M, Michelsen KS. Differential expression of Toll-like receptor 2 (TLR2) and responses to TLR2 ligands between human and murine vascular endothelial cells. J Endoxtin Res 2007, 13:281-296.
53. Uronen-Hansson H, Allen J, Osman M, Squires G, Klein N, Callard RE. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology 2004, 111:173-178.
54. Hornef MW, Normark BH, Vandewalle A, Normark S. Intracellular recognition of lipopolysaccharide by Toll-like receptor 4 in intestinal epithelial cells. J Exp Med 2003, 198:1225-1235.
55. Souza-Fonseca-Guimaraes F, Parlato M, Fitting C, Cavaillon JM, Adib-Conquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J Immunol 2012, 188:5850-5858.
56. Oberholzer A, Harter L, Feilner A, Steckholzer U, Trentz O, Ertel W. Differential effect of caspase inhibition on proinflammatory cytokine release in septic patients. Shock 2000, 14:253-258.
57. Hiraki S, Ono S, Tsujimoto H, Kinoshita M, Takahata R, Miyazaki H, Saitoh D, Hase K. Neutralization of interleukin-10 or transforming growth factor-beta decreases the percentages of CD4(+)CD25(+)Foxp3(+) regulatory T cells in septic mice, thereby leading to an improved survival. Surgery 2012, 151:313-322.
58. Scott MJ, Hoth JJ, Turina M, Woods DR, Cheadle WG. Interleukin-10 suppresses natural killer cell but not natural killer T cell activation during bacterial infection. Cytokine 2006, 33:79-86.
59. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA-J Am Med Assoc 2011, 306:2594-2605.
60. Puente J, Carvajal T, Parra S, Miranda D, Sepulveda C, Wolf ME, Mosnaim AD. In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2. Int J Clin Pharmacol Ther Toxicol 1993, 31:271-275.
61. Melder RJ, Ho M. Modulation of natural-killer cell-activity in mice after interferon induction - depression of activity and depression of in vitro enhancement by interferon. Infect Immun 1982, 36:990-995.
62. Toft P, Dagnaes-Hansen F, Tonnesen E, Basse PM. The effect of surgical stress and endothelin-induced sepsis on the NK-cell activity, distribution and pulmonary clearance of YAC-1 and melanoma cells. Apmis 1999, 107:359-364.
63. Hirsh M, Kaplan V, Dyugovskaya L, Krausz MM. Response of lung NK1.1-positive natural killer cells to experimental sepsis in mice. Shock 2004, 22:40-45.
64. Toliver-Kinsky TE, Varma TK, Lin CY, Herndon DN, Sherwood ER. Interferon-gamma production is suppressed in thermally injured mice: Decreased production of regulatory cytokines and corresponding receptors. Shock 2002, 18:322-330.
65. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, Osborne DF, Clark AT, Coopersmith CM, McDunn JE, Hotchkiss RS. IL-15 Prevents Apoptosis, Reverses Innate and Adaptive Immune Dysfunction, and Improves Survival in Sepsis. J Immunol 2010, 184:1401-1409.